c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer
1994 · New England Journal of Medicine · 968 citations
https://doi.org/10.1056/nejm199405053301802
A
Ann D. Thor
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
298
Papers
22.9K
Citations
76
h-index
177
i10-index
Ann D. Thor is an academic researcher from University of Colorado Anschutz Medical Campus. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Monoclonal and Polyclonal Antibodies Research & Breast Cancer Treatment Studies. The author has an h-index of 76, co-authored 254 publications.
ORCID: 0000-0001-7725-1869Papers by this author
workserbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer
1998 · JNCI Journal of the National Cancer Institute · 615 citations
https://doi.org/10.1093/jnci/90.18.1346
HER2 and Response to Paclitaxel in Node-Positive Breast Cancer
2007 · New England Journal of Medicine · 604 citations
https://doi.org/10.1056/nejmoa071167
Loss of Heterozygosity in Normal Tissue Adjacent to Breast Carcinomas
1996 · Science · 587 citations
https://doi.org/10.1126/science.274.5295.2057
ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization.
1992 · Proceedings of the National Academy of Sciences · 552 citations
https://doi.org/10.1073/pnas.89.12.5321
Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro
2009 · Cell Cycle · 522 citations
https://doi.org/10.4161/cc.8.6.7933
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat